NSCLC Study Makes ‘COMPELling’ Case to Continue EGFR Inhibitor Beyond Progression

(MedPage Today) — Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued osimertinib plus chemotherapy, a…